Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells
- 1k Downloads
To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line.
The NLC was prepared by a hot homogenization method and characterized for size, zeta potential, entrapment efficiency (EE) and drug loading (DL). Drug release was evaluated by dialysis in complete DMEM, and NLC aggregation was assayed in the presence of serum. The cytotoxicity of formulations, doxorubicin uptake or penetration were evaluated in MCF-7 and MCF-7/Adr as monolayer or spheroid models.
The formulation had a size of about 80 nm, negative zeta potential, EE of 99%, DL of 31 mg/g, a controlled drug release in DMEM and no particles aggregation in presence of serum. The NLC loaded with doxorubicin and DHA showed the same activity as free drugs against MCF-7 but a stronger activity against MCF-7/Adr cells. In monolayer model, the doxorubicin uptake as free and encapsulated form was similar in MCF-7 but higher for the encapsulated drug in MCF-7/Adr, suggesting a bypassing of P-glycoprotein bomb efflux. For spheroids, the NLC loaded with doxorubicin and DHA showed a prominent cytotoxicity and a greater penetration of doxorubicin.
These findings suggest that the co-encapsulation of doxorubicin and DHA in NLC enhances the cytotoxicity and overcomes the doxorubicin resistance in MCF-7/Adr.
KEY WORDScancer therapy docosahexaenoic acid doxorubicin nanostructured lipid carrier resistance overcoming
Drug delivery system
Enhanced permeability and retention
Nanostructured lipid carrier
Solid lipid nanoparticles
ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by “Minas Gerais State Agency for Research and Development” (FAPEMIG, Brazil) and by the Brazilian agencies. The authors wish to kindly thank Dr. William Hartner for his helpful advice in editing this manuscript. The authors state no conflict of interest and have received no payment in preparation of this manuscript. All authors have approved the final article.
- 5.Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19(6):1707–15.PubMedGoogle Scholar
- 21.Radtke M, Müller RH. NLC-nanostructured lipid carriers: the new generation of lipid drug carriers. New Drugs. 2001;2:48–52.Google Scholar
- 35.Needham D, Ponce A. Nanoscale drug delivery vehicles for solid tumors: a new paradigm for localized drug delivery using temperature sensitive liposomes. In: Amiji MM, editor. Nanotechnology for cancer therapy. Boca Raton: CRC Press, LLC (a subsidiary of Taylor and Francis); 2007. p. 677–719.Google Scholar
- 39.Dufau I, Frongia C, Sicard F, Dedieu L, Cordelier P, Ausseil F, et al. Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer. 2012;12(15):1–11.Google Scholar